RIRaquel Keiko de Luca Ito

Raquel Keiko de Luca Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Raquel Keiko de Luca Ito has a total of 20 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Mycobacterium kansasii in cancer patients: a 13-case series

    by Patrícia Rodrigues Bonazzi, Giovanni Mollo Baia, William Kazunori Sekiguchi, Adriana Satie Gonçalves Kono Magri, Raquel Keiko de Luca Ito, Karim Yaqub Ibrahim, Odeli Nicole Encinas Sejas, Edson Abdala

    Mycobacterium kansasii comprises one of the most common and most pathogenic nontuberculous mycobacteria, particularly in immunocompromised individuals. This retrospective observational study aimed to describe the epidemiology, clinical characteristics, and outcomes of M. kansasii infections in 13 cancer patients from Instituto do Cancer do Estado de Sao Paulo, Brazil, from January 2011 to September 2023. Of the 19 initial positive cultures, 13 fully met diagnostic criteria for M. kansasii infections. Solid tumors occurred the most (69.2%), and only 38.4% of patients were undergoing chemotherapy at diagnosis. Smoking was the most frequent previous characteristic in these cases (76.9%). Fever (53.4%), cough (46.1%) and dyspnea (30.7%) were the most common symptoms. Multiple nodules (46.1%) and cavities (46.1%) were the most common radiological findings. Overall, seven patients (53.8%) received at least 12 months of therapy. One-year overall mortality totaled 38.4-22.2% in patients with solid tumors and 75% in patients with hematologic malignancies. In conclusion, M. kansasii infections were predominantly pulmonary in this series of cancer patients, which showed a high frequency of other respiratory comorbidities, especially smoking. Mortality occurred in several patients, particularly among those with hematological malignancies.

  • Open Access

    High azole MICs in Fusarium spp.: a key factor in treatment decisions for cancer patients?

    by Raquel Keiko de Luca Ito, Marcia de Souza Carvalho Melhem, Lucas Xavier Bonfietti, Milena Dropa, Juliana Possatto Fernandes Takahashi, Rogério Antonio de Oliveira, Dulcilena de Matos Castro e Silva, Maria Emília Batista de Sousa, Patrícia Rodrigues Bonazzi Pontes, Vítor Falcão de Oliveira, et al.

    Invasive fusariosis (IF) is an exceptionally severe disease, particularly affecting patients with prolonged neutropenia. Even with antifungal therapy, mortality rates remain high, emphasizing the need for stringent control over hospital environment and further research to enhance patient outcomes. This study aims to assess the antifungal susceptibility of clinical and environmental Fusarium isolates and their clinical relevance in a cancer hospital. Sixteen environmental and 21 clinical isolates were identified, with the Fusarium solani species complex being the most common. Amphotericin B demonstrated in vitro activity, but most isolates exhibited elevated minimum inhibitory concentrations (MICs) for azoles. A total of 80% of patients had IF, primarily those with hematological malignancies, and the 30-day mortality rate was 43.8%. Isolates with elevated MICs were often managed with combination therapy. In conclusion, elevated azole MICs may lead to increased use of combination therapy in real-world clinical settings. Our findings emphasize the importance of careful interpretation of antifungal susceptibility testing results in IF management.